S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00054054
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating patients with stage III or stage IV head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2011
Locations: Cancer Research Center at Boston Medical Center, Boston, Massachusetts
Conditions: Head and Neck Cancer
Register for Updates
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
NCT00083083
Unknown
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2011
Locations: Dana-Farber Partners Cancer Care, Boston, Massachusetts +2 locations
Conditions: Lung Cancer
Register for Updates
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
NCT00165139
Completed
The main purpose of this study is to determine the short and long term side effects of a very intensive treatment, which includes combinations of chemotherapy drugs followed by radiation therapy and two transplants supported by peripheral blood progenitor cells (stem cells), for children with advanced stage neuroblastoma and sarcomas.
Gender:
ALL
Ages:
19 years and below
Trial Updated:
10/30/2009
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Neuroblastoma, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma
Register for Updates
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT00402545
Completed
The purpose of this research study is to determine the safest and most effective dose of 5-FU that can be given with docetaxel (Taxotere), Cisplatin and cetuximab to patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. We will also be studying the toxicity of this regimen of 4 drugs and the tumor response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2009
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Head and Neck Neoplasms
Register for Updates
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
NCT00069966
Unknown
RATIONALE: Drugs used in chemotherapy, such as pixantrone, cytarabine, methylprednisolone, and cisplatin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed aggressive non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2009
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Lymphoma
Register for Updates
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
NCT00087698
Completed
This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the cancer returns and if so, where, will also be monitored.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2009
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts
Conditions: Pleural Neoplasms
Register for Updates
Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus
NCT00165191
Completed
The purpose of this study is to collect information on the anti-tumor activity of the combination doxorubicin, cisplatin, and 5-fluorouracil when given to patients with advanced esophageal or gastric adenocarcinoma. We will also be collecting information about the side effects and safety of this combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2009
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Adenocarcinoma of Stomach, Adenocarcinoma of GE Junction, Adenocarcinoma of Esophagus
Register for Updates
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
NCT00165464
Completed
This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and bad) the combination may have on the patients cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2009
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Esophageal Cancer, Gastric Cancer, GE Junction Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx
NCT00004164
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have stage IIB, stage III, or stage IV cancer of the nasopharynx.
Gender:
ALL
Ages:
All
Trial Updated:
02/06/2009
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Head and Neck Cancer
Register for Updates
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT00139230
Completed
The purpose of this study is to further test a combination chemotherapy regimen for the treatment of squamous cell carcinoma of the head and neck and to see if the addition of supportive medicine can help reduce the side effects of these drugs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2008
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Squamous Cell Carcinoma, Carcinoma of Head/Neck
Register for Updates
Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck
NCT00139243
Completed
The purpose of this study is to determine the safety and maximum tolerated dose of the combination taxotere, cisplatin, 5-fluorouracil and leucovorin. We will also preliminarily assess whether the combination is effective in treating squamous cell carcinoma of the head and neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2008
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Squamous Cell Carcinoma, Carcinoma of Head and/or Neck
Register for Updates
Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
NCT00123825
Completed
In the United States, the incidence of biliary tract cancer and gallbladder cancer has been estimated to be 6,000-8,000 patients per year. Currently, there is no standard therapy for these tumors once the disease has spread and is inoperable. Recent small studies with gemcitabine have shown a positive response rate. The investigators plan to test the combination of gemcitabine with cisplatin for biliary tract and gallbladder cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2007
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Gallbladder Cancer, Biliary Tract Cancer
Register for Updates